New drugs in the treatment of psoriasis

Bibliography

• BERNARD BA, ASSELINEAU D, SCHAFFAR-DESHAYES L,DARMON MY: Abnormal sequence of expression of differentiation markers in psoriatic epidermis: inversion of two steps in the differentiation program? J. Invest. Dermatol. (1988) 90:801–805.
   PubMed Web of Science ®Google Scholar
• HOHL D: Expression patterns of loricrin in dermato-logical disorders. Am. J. Dermatopathol (1993) 15:20–27.
   PubMed Web of Science ®Google Scholar
• SCHROEDER WT, THACHER SM, STEWART-GALETKA S etal: Type I keratinocyte transglutaminase: expression in human skin and psoriasis. J. Invest. Dermatol. (1992) 99:27–34.
   PubMed Web of Science ®Google Scholar
• MADSEN P, RASMUSSEN HH, LEFFERS H et al.: Molecularcloning, occurrence, and expression of a novel partially secreted protein `psoriasin' that is highly up-regulated in psoriatic skin. J. Invest. Dermatol. (1991) 97:701–712.
   PubMed Web of Science ®Google Scholar
• NONOMURA K, YAMANISHI K, HOSOKAWA Y et al: Localization of transglutaminase 1 mRNA in normal and psoriatic epidermis by non-radioactive in situ hybridization. Br. J. Dermatol. (1993) 128:23–28.
   PubMed Web of Science ®Google Scholar
• SCHALKWIJK J, VAN VLIJMEN IM, ALKEMADE JA, DE JONGH GJ: Immunohistochemical localization of SKALP/elafin in psoriatic epidermis. J. Invest. Dermatol. (1993) 100:390–393.
   PubMed Web of Science ®Google Scholar
• THALER M, FUKUYAMA K, EPSTEIN WL, FISHER KA:Comparative studies of keratins isolated from psoriasis and atopic dermatitis. J. Invest. Dermatol. (1980) 75:156–158.
   PubMed Web of Science ®Google Scholar
• THEWES M, STADLER R, KORGE B, MISCHKE D: Normalpsoriatic epidermis expression of hyperproliferation associated keratins. Arch. Dermatol Res. (1991) 283:465–471.
   PubMed Web of Science ®Google Scholar
• SCHULZ BS, MICHEL G, WAGNER S et al: Increasedexpression of epidermal 11-8 receptor in psoriasis. Down regulation by FK-506 in vitro. J. Immunol. (1993) 151:4399–4406.
   PubMed Web of Science ®Google Scholar
• DEBETS R, HEGMANS JP, TROOST RJ, BENNER R, PRENSEP: Enhanced production of biologically active interleukin-1 alpha and interleukin-1 beta by psoriatic epidermal cells ex vivo: evidence of increased cytosolic interleukin-1 beta levels and facilitated interleukin-1 release. Eur. J. Immunol. (1995) 25:1624–1630.
   PubMed Web of Science ®Google Scholar
• GROSSMAN RP, KRUEGER J, YOURISH D et al.:Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. Proc. Nad Acad. Sci. USA (1989) 86:6367–6371.
   PubMed Web of Science ®Google Scholar
• NANNEY LB, STOSCHECK CM, MAGID M, KING LE, JR.: Altered [1251]epidermal growth factor binding and receptor distribution in psoriasis. J. Invest. Dermatol. (1986) 86:260–265.
   Google Scholar
• ELDER JT, FISHER GJ, LINDQUIST PB et al.: Overexpres-sion of transforming growth factor alpha in psoriatic epidermis. Science (1989) 243:811–814.
   PubMed Web of Science ®Google Scholar
• COOK PW, PITTELKOW MR, KEEBLE WW et al.: Amphiregulin messenger RNA is elevated in psoriatic epidermis and gastrointestinal carcinomas. Cancer Res. (1992) 52:3224–3227.
   PubMed Web of Science ®Google Scholar
• BAADSGAARD 0, FISHER G, VOORHEES JJ, COOPER KD:The role of the immune system in the pathogenesis of psoriasis. J. Invest. Dermatol. (1990) 95:32S–34S.
   Google Scholar
• CHAMBON P: The retinoid signaling pathway: molecular and genetic analyses. Sem. Cell Biol. (1994) 5:115–125.
   Google Scholar
• •Good review of the retinoid receptors and retinoid signalling.
   Google Scholar
• MANGELSDORF DJ, UMESONO K, EVANS RM: The retinoid receptors. In: The Retinoids: Biology, Chemistry and Medicine (1994)319–349.
   Google Scholar
• •See reference [16] for annotation.
   Google Scholar
• NAGPAL S, FRIANT S, NAKSHATRI H, CHAMBON P: RARsand ID/Rs: evidence for two autonomous transactiva-tion functions (AF-1 and AF-2) and heterodimerization in vivo. EMBO J (1993) 12:2349–2360.
   PubMed Web of Science ®Google Scholar
• DISEPIO D, MALHOTRA M, CHANDRARATNA RA, NAGPALS: Retinoic acid receptor-nuclear factor-interleukin 6 antagonism. A novel mechanism of retinoid-dependent inhibition of a keratinocyte hyperprolif-erative differentiation marker. J. Biol. Chem. (1997) 272:25555–25559.
   Google Scholar
• ORFANOS CE, STADLER R, GOLLNICK H, TSAMBAOS D:Current developments of oral retinoid therapy with three generations of drugs. Non-aromatic, monoaro-matic and polyaromatic retinoids (arotinoids). Curr. Probl. Dermatol. (1985) 13:33–49.
   PubMedGoogle Scholar
• ORFANOS CE, EHLERT R, GOLLNICK H: The retinoids. A review of their clinical pharmacology and therapeutic use. Drugs (1987) 34:459–503.
   Google Scholar
• NAGPAL S, ATHANIKAR J, CHANDRARATNA RAS: Separa-tion of transactivation and AP1 antagonism functions of retinoic acid receptor a. J. Biol. Chem. (1995) 270:923–927.
   PubMed Web of Science ®Google Scholar
• •Shows transactivation and transrepression are separable functions of the retinoid receptor.
   Google Scholar
• WEINSTEIN GD: Safety, efficacy and duration of therapeutic effect of tazarotene used in the treatment of plaque psoriasis. Br. J. Dermatol. (1996) 135 (Suppl. 49):32–36.
   Google Scholar
• KRUEGER GG, DRAKE LA, ELIAS PM et al.: The safety and efficacy of tazarotene gel, a topical acetylenic retinoid, in the treatment of psoriasis. Arch. Dermatol (1998) 134:57–60.
   PubMed Web of Science ®Google Scholar
• KOO J, LEBWOHL M: Duration of remission of psoriasistherapies. J. Am. Acad. Dermatol. (1999) 41:51–59.
   PubMed Web of Science ®Google Scholar
• •Suggests retinoids and steroids have different mechanisms of action.
   Google Scholar
• MARKS R: Early clinical development of tazarotene. Br. Dermatol. (1996) 135 (Suppl. 49):26–31.
   Google Scholar
• MARCHETTI A, LAPENSEE K, AN P: A pharma-coeconomic analysis of topical therapies for patients with mild- to-moderate stable plaque psoriasis: a US study. Clin. Ther. (1998) 20:851–869.
   PubMed Web of Science ®Google Scholar
• GOLLNICK HP, FINZI AF, MARKS R et al.: Optimising the use of tazarotene in clinical practice: Consensus statement from the European Advisory Panel for Tazarotene. Dermatology (1999) 199:40–46.
   PubMed Web of Science ®Google Scholar
• CHANDRARATNA RA: Tazarotene-first of a new genera-tion of receptor-selective retinoids. Br. J. Dermatol (1996) 135 (Suppl. 49):18–25.
   Google Scholar
• ESGLEYES-RIBOT T, CHANDRARATNA RA, LEW-KAYA DA, SEFTON J, DUVIC M: Response of psoriasis to a new topical retinoid, AGN 190168. J. Am. Acad. Dermatol (1994) 30:581–590.
   PubMed Web of Science ®Google Scholar
• NAGPAL S, THACHER SM, PATEL S et al.: Negative regula-tion of two hyperproliferative keratinocyte markers by a retinoic acid receptor-specific retinoid: Insight into the mechanism of retinoid action in psoriasis. Cell Growth Different. (1996) 7:1783–1791.
   PubMedGoogle Scholar
• GRIFFITHS CEM, VOORHEES JJ, NICKOLOFF BJ: Charac-terization of intercellular adhesion molecule-1 and HLA-DR expression in normal and inflamed skin: Modulation by recombinant gamma interferon and tumor necrosis factor. J. Am. Acad. Dermatol (1989) 20:617–629.
   PubMed Web of Science ®Google Scholar
• BECHEREL P-A, LE GOFF L, KTORZA S et al.:CD23-mediated nitric oxide synthase pathway induction in human keratinocytes is inhibited by retinoic acid derivatives. J. Invest. Derm. (1996) 106:1182–1186.
   PubMed Web of Science ®Google Scholar
• NAGPAL S, PATEL S, ASANO AT et al.: Tazarotene-Induced Gene 1 (TIG1), a novel retinoic acid receptor-responsive gene in skin. J. Invest. Dermatol. (1996) 106:269–274.
   PubMed Web of Science ®Google Scholar
• NAGPAL S, PATEL S, JACOBE H et al.: Tazarotene-inducedgene 2 (TIG2), a novel retinoid-responsive gene in skin. J. Invest. Dermatol (1997) 109:91–95.
   PubMed Web of Science ®Google Scholar
• DISEPIO D, GHOSN C, ECKERT RL et al.: Identificationand characterization of a retinoid-induced class II tumor suppressor/growth regulatory gene. Proc. Natl. Acad. Sci. USA (1998) 95:14811–14815.
   PubMed Web of Science ®Google Scholar
• HET Y-J, PATTOLI M, DAVERN L et al.: Suppression of IL-8expression and skin inflammation by a retinoic acid recepor antagonist BM5189453. FASEB J. (1998) 12:A1464. FELDMAN D, CHEN T, HIRST M et al.: Demonstration of 1,25-dihydroxyvitamin D3 receptors in human skin biopsies. J. Clin. Endocrinol Metab. (1980) 51:1463–1465.
   Google Scholar
• HOSOMI J, HOSOI J, ABE E, SUDA T, KUROKI T: Regula- tion of terminal differentiation of cultured mouse epidermal cells by 1 alpha,25-dihydroxyvitamin D3. Endocrinology (1983) 113: 1950-1957.
   Google Scholar
• MORIMOTO S, KUMAHARA Y: A patient with psoriasis cured by 1 alpha-hydroxyvitamin D3. Med. J. Osaka Univ. (1985) 35:51–54.
   PubMedGoogle Scholar
• TAKAMOTO S, ONISHI T, MORIMOTO S et al.: Effect of 1 alpha-hydroxycholecalciferol on psoriasis vulgaris: a pilot study. Calcif Tissue Int. (1986) 39:360–364.
   PubMed Web of Science ®Google Scholar
• MORIMOTO S, YOSHIKAWA K, KOZUKA T et al.: An open study of vitamin D3 treatment in psoriasis vulgaris. Br. Dermatol (1986) 115:421–429.
   PubMed Web of Science ®Google Scholar
• PEREZ A, RAAB R, CHEN TC, TURNER A, HOLICK MF: Safety and efficacy of oral calcitriol (1,25-dihydroxyvitamin D3) for the treatment of psoriasis. Br. J. Dermatol. (1996) 134:1070–1078.
   PubMed Web of Science ®Google Scholar
• PEREZ A, CHEN TC, TURNER A et al.: Efficacy and safety of topical calcitriol (1,25-dihydroxyvitamin D3) for the treatment of psoriasis. Br. J. Dermatol. (1996) 134:238–246.
   PubMed Web of Science ®Google Scholar
• HUCKINS D, FELSON DT, HOLICK M: Treatment of psoriatic arthritis with oral 1,25-dihydroxyvitamin D3: a pilot study. Arthritis Rheum. (1990) 33:1723–1727.
   PubMed Web of Science ®Google Scholar
• KRAGBALLE K: Calcipotriol: a new drug for topicalpsoriasis treatment. PharmacoL ToxicoL (1995) 77:241–246.
   PubMedGoogle Scholar
• DWYER C, CHAPMAN RS: Calcipotriol and hypercal-caemia. Lancet (1991) 338:764–765.
   PubMed Web of Science ®Google Scholar
• BOURKE JF, BERTH-JONES J, IQBAL SJ, HUTCHINSON PE: High-dose topical calcipotriol in the treatment of extensive psoriasis vulgaris. Br. J. Dermatol. (1993) 129:74–76.
   PubMed Web of Science ®Google Scholar
• BRUCE S, EPINETTE WW, FUNICELLA T et al.: Compara-tive study of calcipotriene (MC 903) ointment and fluocinonide ointment in the treatment of psoriasis. J. Am. Acad. Dermatol. (1994) 31:755–759.
   PubMed Web of Science ®Google Scholar
• RAMSAY CA, BERTH-JONES J, BRUNDIN G et al.: Long-term use of topical calcipotriol in chronic plaque psoriasis. Dermatology (1994) 189:260–264.
   PubMed Web of Science ®Google Scholar
• KRAGBALLE K, BARNES L, HAMBERG KJ et al.: Calcipo-triol cream with or without concurrent topical corticosteroid in psoriasis: tolerability and efficacy. Br. J. Dermatol. (1998) 139:649–654.
   PubMed Web of Science ®Google Scholar
• •Combination therapy with corticosteroid is more tolerable and efficacious than calcipotriol alone.
   Google Scholar
• MOLIN L: Topical calcipotriol combined with phototherapy for psoriasis. The results of two randomized trials and a review of the literature. Calcipotriol-UVB Study Group. Dermatology (1999) 198:375–381.
   Google Scholar
• MATSUNAGA T, YAMAMOTO M, MIMURA H et al.: 1,24(R)-dihydroxyvitamin D3, a novel active form of vitamin D3 with high activity for inducing epidermal differentiation but decreased hypercalcemic activity. J. Dermatol. (1990) 17:135–142.
   PubMedGoogle Scholar
• KATO T, TERUI T, TAGAMI H: Topically active vitamin D3 analogue, 1 alpha,24-dihydroxy- cholecalciferol, has an anti-proliferative effect on the epidermis of guinea pig skin. Br. J. Dermatol. (1987) 117:528–530.
   PubMed Web of Science ®Google Scholar
• VAN DE KERKHOF PC, WERFEL T, HAUSTEIN UF et al.: Tacalcitol ointment in the treatment of psoriasis vulgaris: a multicentre, placebo-controlled, double-blind study on efficacy and safety. Br. J. Dermatol. (1996) 135:758–765.
   PubMed Web of Science ®Google Scholar
• KOIZUMI H, KAPLAN A, SHIMIZU T, OHKAWARA A: 1,25-Dihydroxyvitamin D3 and a new analogue, 22-oxacalcitriol, modulate proliferation and interleukin-8 secretion of normal human keratino-cytes. j Dermatol. Sci. (1997) 15:207–213.
   PubMed Web of Science ®Google Scholar
• JN NB, ASHTON RE, MARKS R, HARRIS RI, BERTH-JONES J:Topical maxacalcitol for the treatment of psoriasis vulgaris: a placebo- controlled, double-blind, dose-finding study with active comparator. Br. J. Dermatol. (1999) 141:274–278.
   PubMed Web of Science ®Google Scholar
• BOEHM MF, FITZGERALD P, ZOU A et al. Novel nonsecosteroidal vitamin D mimics exert VDR-modulating activities with less calcium mobilization than 1,25-dihydroxyvitamin D3. Chem. Biol. (1999) 6:265–275.
   PubMed Web of Science ®Google Scholar
• BAKER AR, MCDONNELL DP, HUGHES M et al.: Cloningand expression of full-length cDNA encoding human vitamin D receptor. Proc. Natl. Acad. Sci. USA (1988) 85:3294–3298.
   PubMed Web of Science ®Google Scholar
• CARLBERG C, BENDIK I, WYSS A et al: Two nuclearsignalling pathways for vitamin D. Nature (1993) 361:657–660.
   PubMed Web of Science ®Google Scholar
• DI CUNTO F, TOPLEY G, CALAUTTI E et al.: Inhibitoryfunction of p21Cipl/WAF1 in differentiation of primary mouse keratinocytes independent of cell cycle control. Science (1998) 280:1069–1072.
   PubMed Web of Science ®Google Scholar
• LIU M, LEE MH, COHEN M, BOMMAKANTI M, FREEDMANLP: Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev. (1996) 10:142–153.
   PubMed Web of Science ®Google Scholar
• MICHEL G, GAILIS A, JARZEBSKA-DEUSSEN B et al:1,25-(OH)2-vitamin D3 and calcipotriol induce IL-10 receptor gene expression in human epidermal cells. Inflamm. Res. (1997) 46:32–34.
   PubMed Web of Science ®Google Scholar
• KANG S, YI S, GRIFFITHS CE et al: Calcipotriene-inducedimprovement in psoriasis is associated with reduced interleukin-8 and increased interleukin-10 levels within lesions. Br. J. Dermatol (1998) 138:77–83.
   PubMed Web of Science ®Google Scholar
• MULLER K, BENDTZEN K: 1,25-Dihydroxyvitamin D3 asa natural regulator of human immune functions. J. Inves. Dermatol. Symp. Proc. (1996) 1:68–71.
   PubMedGoogle Scholar
• OXHOLM A, OXHOLM P, STABERG B, BENDTZEN K: Expression of interleukin-6-like molecules and tumour necrosis factor after topical treatment of psoriasis with a new vitamin D analogue (MC 903). Acta Derm. Venereol. (1989) 69:385–390.
   PubMed Web of Science ®Google Scholar
• MATSUMOTO K, HASHIMOTO K, NISHIDA Y, HASHIRO M, YOSHIKAWA K: Growth-inhibitory effects of 1,25-dihydroxyvitamin D3 on normal human keratinocytes cultured in serum-free medium. Biochem. Biophys. Res. Commun. (1990) 166:916–923.
   PubMed Web of Science ®Google Scholar
• TOWERS TL, FREEDMAN LP: Granulocyte-macrophagecolony-stimulating factor gene transcription is directly repressed by the vitamin D3 receptor. Implica-tions for allosteric influences on nuclear receptor structure and function by a DNA element. J. Biol. Chem. (1998) 273:10338–10348.
   Google Scholar
• TSOUKAS CD, PROVVEDINI DM, MANOLAGAS SC: 1,25-dihydroxyvitamin D3: a novel immunoregulatory hormone. Science (1984) 224:1438–1440.
   PubMed Web of Science ®Google Scholar
• TOWERS TL, STAEVA TP, FREEDMAN LP: A two-hit mechanism for vitamin D3-mediated transcriptional repression of the granulocyte-macrophage colony-stimulating factor gene: vitamin D receptor competes for DNA binding with NFAT1 and stabilizes c-Jun. Mol. Cell. Biol. (1999) 19:4191–4199.
   PubMed Web of Science ®Google Scholar
• BITTINER B, BLEEHEN SS, MACNEIL S: 1 alpha,25(OH)2 vitamin D3 increases intracellular calcium in human keratinocytes. Br. J. Dermatol. (1991) 124:230–235.
   PubMed Web of Science ®Google Scholar
• SLATER SJ, KELLY MB, TADDEO FJ et al: Direct activation of protein kinase C by 1 alpha,25-dihydroxyvitamin D3. J. Biol. Chem. (1995) 270:6639–6643.
   PubMed Web of Science ®Google Scholar
• •References [72-75] suggest non-genomic actions of nuclear receptors.
   Google Scholar
• GNIADECKI R: Activation of Raf-mitogen-activated protein kinase signaling pathway by 1,25-dihydroxyvitamin D3 in normal human keratino-cytes. J. Invest. Dermatol. (1996) 106:1212–1217.
   PubMed Web of Science ®Google Scholar
• •See reference [72] for annotation.
   Google Scholar
• GNIADECKI R: Nongenomic signaling by vitamin D: a new face of Src. Biochem. Pharmacol. (1998) 56:1273–1277.
   Google Scholar
• •See reference [72] for annotation.
   Google Scholar
• GNIADECKI R: Involvement of Src in the vitamin D signaling in human keratinocytes. Biochem. Pharmacol (1998) 55:499–503.
   PubMed Web of Science ®Google Scholar
• •See reference [72] for annotation.
   Google Scholar
• DEFRANCO AL: Signal transduction. Immunosuppres-sants at work. Nature (1991) 352:754–755.
   PubMed Web of Science ®Google Scholar
• MCCAFFREY PG, GOLDFELD AE, RAO A: The role of NFATp in cyclosporin A-sensitive tumor necrosis factor- alpha gene transcription. J. Biol. Chem. (1994) 269:30445–30450.
   PubMed Web of Science ®Google Scholar
• BAKER BS, GRIFFITHS CE, LAMBERT S et al.: The effects ofcyclosporin A on T lymphocyte and dendritic cell sub-populations in psoriasis. Br. J. Dermatol. (1987) 116:503–510.
   PubMed Web of Science ®Google Scholar
• KADUNCE DP, KRUEGER GG: Pathogenesis of psoriasis.Dermatol. Clin. (1995) 13:723–737.
   PubMed Web of Science ®Google Scholar
• •
   Google Scholar
• SHUPACK J, ABEL E, BAUER E et al: Cyclosporine as maintenance therapy in patients with severe psoriasis. J. Am. Acad. Dermatol. (1997) 36:423–432.
   PubMed Web of Science ®Google Scholar
• HERMANN RC, TAYLOR RS, ELLIS CN et al.: Topical cyclosporin for psoriasis: in vitro skin penetration and clinical study. Skin Pharmacol. (1988) 1:246–249.
   PubMedGoogle Scholar
• MKCEON F: When worlds collide: immunosuppres-sants meet protein phosphatases. Cell (1991) 66:823–826.
   PubMed Web of Science ®Google Scholar
• Systemic tacrolimus (FK 506) is effective for thetreatment of psoriasis in a double-blind, placebo-controlled study. The European FK 506 Multicentre Psoriasis Study Group. Arch. Dermatol. (1996) 132:419–423.
   Google Scholar
• JEGASOTHY By, ACKERMAN CD, TODO S et al.: Tacrolimus (FK 506)-a new therapeutic agent for severe recalcitrant psoriasis. Arch. Dermatol. (1992) 128:781–785.
   PubMed Web of Science ®Google Scholar
• ZONNEVELD IM, RUBINS A, JABLONSKA S et al.: Topicaltacrolimus is not effective in chronic plaque psoriasis. A pilot study. Arch. Dermatol. (1998) 134:1101–1102.
   PubMed Web of Science ®Google Scholar
• REMITZ A, REITAMO S, ERKKO P, GRANLUND H, LAUERMA AT: Tacrolimus ointment improves psoriasis in a microplaque assay. Br. J. Dermatol. (1999) 141:103–107.
   PubMed Web of Science ®Google Scholar
• MCELWEE KJ, RUSHTON DH, TRACHY R, OLIVER RF: Topical FK506: a potent immunotherapy for alopecia areata? Studies using the Dundee experimental bald rat model. Br. J. Dermatol (1997) 137:491–497.
   PubMed Web of Science ®Google Scholar
• VAN LEENT EJ, GRABER M, THURSTON M eta].: Effective-ness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis. Arch. Dermatol. (1998) 134:805–809.
   Google Scholar
• RAPPERSBERGER K, MEINGASSNER JG, FIALLA R et al:Clearing of psoriasis by a novel immunosuppressive macrolide. J. Invest. Dermatol. (1996) 106:701–710.
   PubMed Web of Science ®Google Scholar
• MROWIETZ U, GRAEBER M, BRAUTIGAM M et al.: The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion. Br. Dermatol (1998) 139:992–996.
   PubMed Web of Science ®Google Scholar
• MOLLISON KW, FEY TA, GAUVIN DM et al.: Discovery of ascomycin analogs with potent topical but weak systemic activity for treatment of inflammatory skin diseases. Curr. Pharm. Des. (1998) 4:367–379.
   PubMed Web of Science ®Google Scholar
• MOLLISON KW, FEY TA, GAUVIN DM et al.: A macrolactam inhibitor of T helper Type 1 and T helper Type 2 cytokine biosynthesis for topical treatment of inflammatory skin diseases. J. Invest. Dermatol (1999) 112:729–738.
   PubMed Web of Science ®Google Scholar
• ARAMBURU J, YAFFE MB, LOPEZ-RODRIGUEZ C et al:Affinity-driven peptide selection of an NFAT inhibitor more selective than cyclosporin A. Science (1999) 285:2129–2133.
   PubMed Web of Science ®Google Scholar
• HAUFS MG, BEISSERT S, GRABBE S, SCHUTTE B, LUGERTA: Psoriasis vulgaris treated successfully with mycophenolate mofetil. Br. J. Dermatol. (1998) 138:179–181.
   PubMed Web of Science ®Google Scholar
• TONG DW, WALDER BK: Widespread plaque psoriasisresponsive to mycophenolate mofetil. Australas. J. Dermatol (1999) 40:135–137.
   PubMed Web of Science ®Google Scholar
• SINTCHAK MD, FLEMING MA, FUTER 0 et al.: Structureand mechanism of inosine monophosphate dehydro-genase in complex with the immunosuppressant mycophenolic acid. Cell (1996) 85:921–930.
   Google Scholar
• VANDERSPEK JC, MINDELL JA, FINKELSTEIN A, MURPHYJR: Structure/function analysis of the transmembrane domain of DAB389- interleukin-2, an interleukin-2 receptor-targeted fusion toxin. The amphipathic helical region of the transmembrane domain is essential for the efficient delivery of the catalytic domain to the cytosol of target cells. J. Biol. Chem. (1993) 268:12077–12082.
   Google Scholar
• GOTTLIEB SL, GILLEAUDEAU P, JOHNSON R et al:Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nature Med. (1995) 1:442–447.
   PubMed Web of Science ®Google Scholar
• BAGEL J, GARLAND WT, BRENEMAN D eta].: Administra-tion of DAB389IL-2 to patients with recalcitrant psoriasis: a double-blind, Phase II multicenter trial. J. Am. Acad. Dermatol. (1998) 38:938–944.
   Google Scholar
• ABRAMS JR, LEBWOHL MG, GUZZO CA et al.: CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J. Clin. Invest. (1999) 103:1243–1252.
   PubMed Web of Science ®Google Scholar
• MAGILAVY D, MANT T, NORMAN P et al: Pharmacody-namic effects of LFA3TIP (Amevive) in patients with chronic plaque psoriasis (CPP): selective modulation of CD45R0+ lymphocytes. J. Invest. Dermatol. (1999) 112:609.
   Web of Science ®Google Scholar
• MOREL P, REVILLARD JP, NICOLAS JF et al: Anti-CD4 monoclonal antibody therapy in severe psoriasis. J. Autoimmun. (1992) 5:465–477.
   PubMed Web of Science ®Google Scholar
• BACHELEZ H, FLAGEUL B, DUBERTRET L et al.: Treatment of recalcitrant plaque psoriasis with a humanized non- depleting antibody to CD4. J. Autoimmun. (1998) 11:53–62.
   PubMed Web of Science ®Google Scholar
• GOTTLIEB AB, KRUEGER J, LEBWOHL M et al: A multiple dose randomized double-blindplacebo-controlled study to determine the efficacy and safety of a humanized anti-CD4 monoclonal antibody in the treatment of moderate to severe chronic psoriasis vulgaris. J. Invest. Dermatol. (1998) 110:678.
   Web of Science ®Google Scholar
• GOTTLIEB A, KRUEGER J, BRIGHT R et al.: Phase I trial of psoriasis with an anti-CD11A (LFA-1) monoclonal antibody (MAB). J. Invest. Dermatol (1998) 110:679.
   Web of Science ®Google Scholar
• GOTTLIEB A, KRUEGER J, ABDULGHANI A et al.: Psoriasis is clinically and histologically improved by treatment with a humanized anti-CD11a monoclonal antibody (hu1124): Results of a multicenter, multiple ascending dose study. J. Invest. Dermatol (1999) 112:647.
   Web of Science ®Google Scholar
• KRUEGER J, WALTERS I, MIYAZAWA M et al.: Successful in vivo blockade of CD25 (high-affinity IL-2 receptor) on T-cells by administration of humanized antibody to psoriasis patients. J. Invest. Dermatol. (1999) 112:565.
   Web of Science ®Google Scholar
• LEVITZKI A, GAZIT A: Tyrosine kinase inhibition: an approach to drug development. Science (1995) 267:1782–1788.
   PubMed Web of Science ®Google Scholar
• REYNOLDS NJ, MCCOMBIE SW, SHANKAR BB, BISHOP WR, FISHER GJ: SCH 47112, a novel staurosporine derivative, inhibits 12-0- tetradecanoylphorbol-13-acetate-induced inflammation and epidermal hyperplasia in hairless mouse skin. Arch. Dermatol. Res. (1997) 289:540–546.
   PubMed Web of Science ®Google Scholar
• TREPICCHIO WL, WANG L, BOZZA M, DORNER AJ: IL-11 regulates macrophage effector function through the inhibition of nuclear factor-KB. J. Immunol. (1997) 159:5661–5670.
   PubMed Web of Science ®Google Scholar
• TREPICCHIO WL, BOZZA M, PEDNEAULT G, DORNER AJ: Recombinant human IL-11 attenuates the inflamma-tory response through down-regulation of proinflam-matory cytokine release and nitric oxide production. J. Immunol. (1996) 157:3627–3634.
   PubMed Web of Science ®Google Scholar
• ASADULLAH K, STERRY W, STEPHANEK K et al.: IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach. J. Clin. Invest. (1998) 101:783–794.
   Google Scholar
• ASADULLAH K, DOCKE WD, EBELING M et al.: Interleukin 10 treatment of psoriasis: clinical results of a Phase 2 trial. Arch. Dermatol (1999) 135:187–192.
   PubMed Web of Science ®Google Scholar
• LEBWOHL M, POULIN Y: Tazarotene in combination with topical corticosteroids. J. Am. Acad. Dermatol. (1998) 39:S139–143.
   PubMed Web of Science ®Google Scholar
• LEBWOHL MG, BRENEMAN DL, GOFFE BS et al.: Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis. J. Am. Acad. Dermatol (1998) 39:590–596.
   Google Scholar
• LEBWOHL M: Clinical efficacy and safety of tazarotene: optimizing clinical results. Cutts (1998) 61:27–29.
   PubMedGoogle Scholar
• KOO JY: Tazarotene in combination with phototherapy. J. Am. Acad. Dermatol. (1998) 39:S144–148.
   PubMed Web of Science ®Google Scholar